Highlight publications
Craddock, C, Jackson, A, Loke, J, Siddique, S, Hodgkinson, A, Mason, J, Andrew, G, Nagra, S, Malladi, R, Peniket, A, Gilleece, M, Salim, R, Tholouli, E, Potter, V, Crawley, C, Wheatley, K, Protheroe, R, Vyas, P, Hunter, A, Parker, A, Wilson, K, Pavlu, J, Byrne, J, Dillon, R, Khan, N, Mccarthy, N & Freeman, SD 2020, 'Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.20.02308
Freeman, S & Craddock, C 2020, 'Less is not necessarily more: toward a rational selection of the conditioning regimen in acute myeloid leukemia', Journal of Clinical Oncology , vol. 38, no. 12, pp. 1249-1251. https://doi.org/10.1200/JCO.19.03161
Freeman, S, Hills, R, Virgo, P, Khan, N, Couzens, S, Dillon, R, Gilkes, A, Upton, L, Nielsen, OJ, Cavenagh, JD, Jones, G, Khwaja, A, Cahalin, P, Thomas, I, Grimwade, D, Burnett, AK & Russell, NH 2018, 'Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations', Journal of Clinical Oncology , vol. 36, no. 15, pp. 1486-1497. https://doi.org/10.1200/JCO.2017.76.3425
Short, NJ, Zhou, S, Fu, C, Berry, DA, Walter, RB, Freeman, SD, Hourigan, CS, Huang, X, Nogueras, GG, Hwang, H, Qi, X, Kantarjian, H & Ravandi, F 2020, 'Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.', JAMA Oncology, vol. 6, no. 12, pp. 1890-1899. https://doi.org/10.1001/jamaoncol.2020.4600
Schuurhuis, GJ, Heuser, M, Freeman, S, Béné, M-C, Buccisano, F, Cloos, J, Grimwade, D, Haferlach, T, Hills, RK, Hourigan, CS, Jorgensen, JL, Kern, W, Lacombe, F, Maurillo, L, Preudhomme, C, van der Reijden, BA, Thiede, C, Venditti, A, Vyas, P, Wood, BL, Walter, RB, Döhner, K, Roboz, GJ & Ossenkoppele, GJ 2018, 'Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party', Blood. https://doi.org/10.1182/blood-2017-09-801498
Recent publications
Article
Othman, J, Wilhelm-Benartzi, CS, Dillon, R, Knapper, S, Freeman, SD, Batten, LM, Canham, J, Hinson, EL, Wych, J, Betteridge, S, Villiers, W, Kleeman, M, Gilkes, AF, Potter, N, Overgaard, U, Mehta, P, PANAGIOTIS, KOTTARIDIS, Cavenagh, J, Claire Jane Hemmaway, Arnold, C, Dennis, M & Russell, NH 2023, 'A Randomised Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial', Blood Advances. https://doi.org/10.1182/bloodadvances.2023010276
Othman, J, Potter, N, Mokretar, K, Taussig, D, Khan, A, Krishnamurthy, P, Latif, A-L, Cahalin, P, Aries, J, Amer, M, Belsham, E, Conneally, E, Craddock, C, Culligan, D, Dennis, M, Duncan, C, Freeman, SD, Furness, C, Gilkes, A, Gkreka, P, Hodgson, K, Ingram, W, Jain, M, King, A, Knapper, S, Kottaridis, P, McMullin, MF, Mohite, U, Ngu, L, O'Nions, J, Patrick, K, Rider, T, Roberts, W, Severinsen, MT, Storrar, N, Taylor, T, Russell, NH & Dillon, R 2023, 'FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML', Leukemia. https://doi.org/10.1038/s41375-023-01994-x
Freeman, SD, Thomas, A, Thomas, I, Hills, RK, Vyas, P, Gilkes, A, Metzner, M, Jakobsen, NA, Kennedy, A, Moore, A, Almuina, NM, Burns, S, King, S, Andrew, G, Gallagher, KME, Sellar, RS, Cahalin, P, Weber, D, Dennis, M, Mehta, P, Knapper, S & Russell, NH 2023, 'Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial', Blood. https://doi.org/10.1182/blood.2023020630
Loke, J, McCarthy, N, Jackson, A, Siddique, S, Hodgkinson, A, Mason, J, Crawley, C, Gilleece, M, Peniket, A, Protheroe, R, Salim, R, Tholouli, E, Wilson, K, Andrew, G, Dillon, R, Khan, N, Potter, V, Krishnamurthy, P, Craddock, C & Freeman, S 2023, 'Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS', Blood Advances, vol. 7, no. 14, pp. 3666-3676. https://doi.org/10.1182/bloodadvances.2022009493
Mehta, P, Telford, N, Wragg, C, Dillon, R, Freeman, S, Finnegan, D, Hamblin, A, Copland, M & Knapper, S 2023, 'Recommendations for laboratory testing of UK patients with acute myeloid leukaemia', British Journal of Haematology, vol. 200, no. 2, pp. 150-159. https://doi.org/10.1111/bjh.18516
Schulz, E, Aplan, PD, Freeman, SD & Pavletic, SZ 2023, 'Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes', Blood Advances. https://doi.org/10.1182/bloodadvances.2023010098
Short, NJ, Fu, C, Berry, DA, Walter, RB, Freeman, SD, Hourigan, CS, Huang, X, Gonzalez, GN, Hwang, H, Qi, X, Kantarjian, H, Zhou, S & Ravandi, F 2022, 'Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis', Leukemia, vol. 36, pp. 2817–2826. https://doi.org/10.1038/s41375-022-01692-0
Röhnert, MA, Kramer, M, Schadt, J, Ensel, P, Thiede, C, Krause, SW, Bücklein, V, Hoffmann, J, Jaramillo, S, Schlenk, RF, Röllig, C, Bornhäuser, M, McCarthy, N, Freeman, S, Oelschlägel, U & von Bonin, M 2022, 'Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia', Leukemia, vol. 36, no. 9, pp. 2208-2217. https://doi.org/10.1038/s41375-022-01647-5
Tettero, JM, Freeman, S, Buecklein, V, Venditti, A, Maurillo, L, Kern, W, Walter, RB, Wood, BL, Roumier, C, Philippé, J, Denys, B, Jorgensen, JL, Bene, MC, Lacombe, F, Plesa, A, Guzman, ML, Wierzbowska, A, Czyz, A, Ngai, LL, Schwarzer, A, Bachas, C, Cloos, J, Subklewe, M, Fuering-Buske, M & Buccisano, F 2022, 'Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European Leukemianet MRD Working Party', HemaSphere, vol. 6, no. 1, e676, pp. E676. https://doi.org/10.1097/HS9.0000000000000676
Tazi, Y, Arango-Ossa, JE, Zhou, Y, Bernard, E, Thomas, I, Gilkes, A, Freeman, S, Pradat, Y, Johnson, SJ, Hills, R, Dillon, R, Levine, MF, Leongamornlert, D, Butler, A, Ganser, A, Bullinger, L, Döhner, K, Ottmann, O, Adams, R, Döhner, H, Campbell, PJ, Burnett, AK, Dennis, M, Russell, NH, Devlin, SM, Huntly, BJP & Papaemmanuil, E 2022, 'Unified classification and risk-stratification in acute myeloid leukemia', Nature Communications, vol. 13, no. 1, 4622. https://doi.org/10.1038/s41467-022-32103-8
Dillon, R, Maycock, S, Jackson, A, Fox, S, Freeman, S, Craddock, C, Thomas, C, Homer, E, Leahy, J, Mamwell, A, Potter, N, Russell, N, Wei, A, Ommen, HB, Hemmaway, C, Knapper, S & Billingham, L 2022, 'Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial', BMC Cancer, vol. 22, no. 1, 1174. https://doi.org/10.1186/s12885-022-10221-2
Editorial
Freeman, S 2022, 'Delving the depths of MRD negativity in acute myeloid leukemia', Haematologica. https://doi.org/10.3324/haematol.2022.280747
Freeman, SD & Valk, P 2022, 'Transplant in older adults with AML: genomic wheat and chaff', Blood, vol. 139, no. 24, pp. 3459-3461. https://doi.org/10.1182/blood.2022016195
Review article
DiNardo, CD, Erba, HP, Freeman, SD & Wei, AH 2023, 'Acute myeloid leukaemia', The Lancet, vol. 401, no. 10393, pp. 2073-2086. https://doi.org/10.1016/s0140-6736(23)00108-3
Shallis, RM, Daver, N, Altman, JK, Komrokji, RS, Pollyea, DA, Badar, T, Bewersdorf, JP, Bhatt, VR, de Botton, S, de la Fuente Burguera, A, Carraway, HE, Desai, P, Dillon, R, Duployez, N, El Chaer, F, Fathi, AT, Freeman, SD, Gojo, I, Grunwald, MR, Jonas, BA, Konopleva, M, Lin, TL, Mannis, GN, Mascarenhas, J, Michaelis, LC, Mims, AS, Montesinos, P, Pozdnyakova, O, Pratz, KW, Schuh, AC, Sekeres, MA, Smith, CC, Stahl, M, Subklewe, M, Uy, GL, Voso, MT, Walter, RB, Wang, ES, Zeidner, JF, Žučenka, A & Zeidan, AM 2023, 'Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts', The Lancet Haematology. https://doi.org/10.1016/S2352-3026(23)00159-X